These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 16409833)

  • 41. Prostate specific antigen and other markers for prostate cancer.
    Schröder FH
    J Urol; 2006 Apr; 175(4):1199-200. PubMed ID: 16515959
    [No Abstract]   [Full Text] [Related]  

  • 42. [Modern tumor markers in differential diagnostics of the prostate gland diseases].
    Shaplygin LV; Belokhvostov AS; Galitskiĭ TV
    Voen Med Zh; 2008 Mar; 329(3):45-8. PubMed ID: 18488488
    [No Abstract]   [Full Text] [Related]  

  • 43. What can be concluded from the ERSPC and PLCO trial data?
    Studer UE; Collette L
    Urol Oncol; 2010; 28(6):668-9. PubMed ID: 21062648
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Prostate cancer: is the PSA test the answer?
    Berlin B
    N J Med; 1998 Mar; 95(3):53-5. PubMed ID: 16013148
    [No Abstract]   [Full Text] [Related]  

  • 45. Revisiting my personal decision about prostate-specific antigen testing in 2005.
    Barry MJ
    BJU Int; 2005 Nov; 96(7):954-6. PubMed ID: 16225507
    [No Abstract]   [Full Text] [Related]  

  • 46. How valuable is prostate-specific antigen screening?
    Handler S
    Minn Med; 1996 Jun; 79(6):2. PubMed ID: 8692130
    [No Abstract]   [Full Text] [Related]  

  • 47. Screening for prostate cancer: the role of prostate-specific antigen.
    Ferrer RL
    Md Med J; 1996 Nov; 45(11):938-40. PubMed ID: 8942171
    [No Abstract]   [Full Text] [Related]  

  • 48. Prostate-specific antigen screening for prostate cancer: a decision-analytical perspective.
    Hayes JH; Barry MJ; Kantoff PW; Stahl JE
    BJU Int; 2007 Sep; 100(3):486-8. PubMed ID: 17669139
    [No Abstract]   [Full Text] [Related]  

  • 49. [Screening for prostate cancer: results from the first screening round in the French population of the ERSPC trial].
    Richard F
    Prog Urol; 2009 Jul; 19(7):499-500. PubMed ID: 19559381
    [No Abstract]   [Full Text] [Related]  

  • 50. Screening for prostate cancer: recommendations and rationale.
    Berg AO;
    Am J Nurs; 2003 Mar; 103(3):107-10; discussion 111. PubMed ID: 12626949
    [No Abstract]   [Full Text] [Related]  

  • 51. Tumour markers in prostate cancer: EGTM recommendations. European Group on Tumour Markers.
    Anticancer Res; 1999; 19(4A):2799-801. PubMed ID: 10470244
    [No Abstract]   [Full Text] [Related]  

  • 52. Prostatic specific antigen in prostate cancer.
    Wozniak-Petrofsky J
    Urol Nurs; 1992 Sep; 12(3):104-5. PubMed ID: 1382317
    [No Abstract]   [Full Text] [Related]  

  • 53. [The PSA test--abomination or blessing? Longer follow up necessary to get an answer].
    Aus G
    Lakartidningen; 2010 Feb 17-23; 107(7):422-3. PubMed ID: 20384073
    [No Abstract]   [Full Text] [Related]  

  • 54. Weighing the benefits and downsides of prostate-specific antigen screening.
    Pignone M
    Arch Intern Med; 2009 Sep; 169(17):1554-6. PubMed ID: 19786672
    [No Abstract]   [Full Text] [Related]  

  • 55. Prostate-specific antigen: a misused and maligned prostate cancer biomarker.
    Thompson IM; Tangen CM; Kristal AR
    J Natl Cancer Inst; 2008 Nov; 100(21):1487-8. PubMed ID: 18957671
    [No Abstract]   [Full Text] [Related]  

  • 56. Estimating lead time and overdiagnosis associated with PSA screening from prostate cancer incidence trends.
    Telesca D; Etzioni R; Gulati R
    Biometrics; 2008 Mar; 64(1):10-9. PubMed ID: 17501937
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Specificity of serum prostate-specific antigen determination in the Finnish prostate cancer screening trial.
    Määttänen L; Hakama M; Tammela TL; Ruutu M; Ala-Opas M; Juusela H; Martikainen P; Stenman UH; Auvinen A
    Br J Cancer; 2007 Jan; 96(1):56-60. PubMed ID: 17213825
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Prostate cancer screening.
    Catalona WJ
    BJU Int; 2004 Nov; 94(7):964-6. PubMed ID: 15541107
    [No Abstract]   [Full Text] [Related]  

  • 59. [Legal (liability) aspects of PSA determination].
    Mielke K
    Urologe A; 2006 Jun; 45(6):756-65. PubMed ID: 16788794
    [No Abstract]   [Full Text] [Related]  

  • 60. Mass screening for prostate cancer. The Swedish Council on Technology Assessment in Health Care.
    Int J Cancer Suppl; 1996; 9():1-72. PubMed ID: 8982323
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.